[Can cutaneous intolerance reactions to caryolysine be prevented or controlled?].
D000287:Administration, Topical; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D003877:Dermatitis, Contact / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects*; D011701:PUVA Therapy
D018906:Antineoplastic Agents, Alkylating; D008466:Mechlorethamine